Refine
Document Type
- Article (2)
Language
- English (2) (remove)
Has Fulltext
- yes (2)
Is part of the Bibliography
- no (2)
Keywords
- - (1)
- Cardiovascular disease (1)
- Data and biomaterial collection (1)
- German Centre for Cardiovascular Research (1)
- Research platform (1)
- Standardisation (1)
- cardiomyopathy (1)
- energy metabolism (1)
- heart failure (1)
- multi-omics (1)
Institute
Publisher
- MDPI (1)
- Springer Nature (1)
With more than 25 million people affected, heart failure (HF) is a global threat. As energy
production pathways are known to play a pivotal role in HF, we sought here to identify key metabolic
changes in ischemic- and non-ischemic HF by using a multi-OMICS approach. Serum metabolites and
mRNAseq and epigenetic DNA methylation profiles were analyzed from blood and left ventricular
heart biopsy specimens of the same individuals. In total we collected serum from n = 82 patients
with Dilated Cardiomyopathy (DCM) and n = 51 controls in the screening stage. We identified
several metabolites involved in glycolysis and citric acid cycle to be elevated up to 5.7-fold in DCM
(p = 1.7 × 10−6
). Interestingly, cardiac mRNA and epigenetic changes of genes encoding rate-limiting
enzymes of these pathways could also be found and validated in our second stage of metabolite
assessment in n = 52 DCM, n = 39 ischemic HF and n = 57 controls. In conclusion, we identified a
new set of metabolomic biomarkers for HF. We were able to identify underlying biological cascades
that potentially represent suitable intervention targets.
The German Centre for Cardiovascular Research (DZHK) is one of the German Centres for Health Research and aims to conduct early and guideline-relevant studies to develop new therapies and diagnostics that impact the lives of people with cardiovascular disease. Therefore, DZHK members designed a collaboratively organised and integrated research platform connecting all sites and partners. The overarching objectives of the research platform are the standardisation of prospective data and biological sample collections among all studies and the development of a sustainable centrally standardised storage in compliance with general legal regulations and the FAIR principles. The main elements of the DZHK infrastructure are web-based and central units for data management, LIMS, IDMS, and transfer office, embedded in a framework consisting of the DZHK Use and Access Policy, and the Ethics and Data Protection Concept. This framework is characterised by a modular design allowing a high standardisation across all studies. For studies that require even tighter criteria additional quality levels are defined. In addition, the Public Open Data strategy is an important focus of DZHK. The DZHK operates as one legal entity holding all rights of data and biological sample usage, according to the DZHK Use and Access Policy. All DZHK studies collect a basic set of data and biosamples, accompanied by specific clinical and imaging data and biobanking. The DZHK infrastructure was constructed by scientists with the focus on the needs of scientists conducting clinical studies. Through this, the DZHK enables the interdisciplinary and multiple use of data and biological samples by scientists inside and outside the DZHK. So far, 27 DZHK studies recruited well over 11,200 participants suffering from major cardiovascular disorders such as myocardial infarction or heart failure. Currently, data and samples of five DZHK studies of the DZHK Heart Bank can be applied for.